{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:47:29Z","timestamp":1791323249833,"version":"4.3.1"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T00:00:00Z","timestamp":1454630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0004431","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T18:54:26Z","timestamp":1454698466000},"page":"e0004431","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer"],"prefix":"10.1371","volume":"10","author":[{"given":"Miriam","family":"Bolz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e8le","family":"B\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita M.","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vettiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wulf","family":"Oehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahavir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm S.","family":"Duthie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Pluschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,2,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e911","DOI":"10.1371\/journal.pntd.0000911","article-title":"Ecology and transmission of Buruli ulcer disease: a systematic review","volume":"4","author":"RW Merritt","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Junghanss T, Johnson RC, Pluschke G. Mycobacterium ulcerans disease. Manson\u2019s tropical diseases. 23rd ed. Saunders; 2014. pp. 519\u2013531.","DOI":"10.1016\/B978-0-7020-5101-2.00043-1"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1126\/science.283.5403.854","article-title":"Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence","volume":"283","author":"KM George","year":"1999","journal-title":"Science"},{"key":"ref4","unstructured":"WHO | Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans<\/italic> disease (Buruli ulcer). In: WHO [Internet]. [cited 4 Feb 2014]. Available: http:\/\/www.who.int\/buruli\/information\/antibiotics\/en\/index16.html<\/ext-link>"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0140-6736(09)61962-0","article-title":"Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial","volume":"375","author":"WA Nienhuis","year":"2010","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/AAC.00299-10","article-title":"Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease","volume":"54","author":"FS Sarfo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1128\/AAC.00175-07","article-title":"Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)","volume":"51","author":"A Chauty","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref8","unstructured":"WHO | Laboratory diagnosis of buruli ulcer. In: WHO [Internet]. [cited 2 Jun 2014]. Available: http:\/\/www.who.int\/buruli\/laboratory_diagnosis\/en\/<\/ext-link>"},{"key":"ref9","unstructured":"WHO | Treatment of Mycobacterium ulcerans<\/italic> disease (Buruli Ulcer). In: WHO [Internet]. [cited 11 Sep 2014]. Available: http:\/\/www.who.int\/buruli\/treatment\/en\/<\/ext-link>"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/CVI.00254-06","article-title":"Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans","volume":"13","author":"D Diaz","year":"2006","journal-title":"Clin Vaccine Immunol CVI"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e2904","DOI":"10.1371\/journal.pntd.0002904","article-title":"Late onset of the serological response against the 18 kDa small heat shock protein of Mycobacterium ulcerans in children","volume":"8","author":"K R\u00f6ltgen","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0140-6736(73)92005-9","article-title":"A CONTROLLED TRIAL OF THE TREATMENT OF MYCOBACTERIUM ULCERANS INFECTION WITH CLOFAZIMINE","volume":"302","author":"WDL Revill","year":"1973","journal-title":"The Lancet"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001290","article-title":"Spontaneous Clearance of Mycobacterium ulcerans in a Case of Buruli Ulcer","volume":"5","author":"CL Gordon","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e2252","DOI":"10.1371\/journal.pntd.0002252","article-title":"Geographic distribution, age pattern and sites of lesions in a cohort of Buruli ulcer patients from the Map\u00e9 Basin of Cameroon","volume":"7","author":"MW Bratschi","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00430-009-0109-6","article-title":"Buruli ulcer disease: prospects for a vaccine","volume":"198","author":"K Huygen","year":"2009","journal-title":"Med Microbiol Immunol (Berl)"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/IAI.00889-06","article-title":"Evidence for an intramacrophage growth phase of Mycobacterium ulcerans","volume":"75","author":"E Torrado","year":"2007","journal-title":"Infect Immun"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1462-5822.2005.00546.x","article-title":"Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin","volume":"7","author":"E Coutanceau","year":"2005","journal-title":"Cell Microbiol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.4161\/hv.7.11.17751","article-title":"Buruli ulcer","volume":"7","author":"T Einarsdottir","year":"2011","journal-title":"Hum Vaccin"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e33406","DOI":"10.1371\/journal.pone.0033406","article-title":"Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination","volume":"7","author":"AG Fraga","year":"2012","journal-title":"PloS One"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0035-9203(76)90128-0","article-title":"The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda","volume":"70","author":"PG Smith","year":"1976","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/IAI.72.1.62-65.2004","article-title":"Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease","volume":"72","author":"F Portaels","year":"2004","journal-title":"Infect Immun"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1517\/14712590802631854","article-title":"Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer)","volume":"9","author":"D Sch\u00fctte","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.vaccine.2015.03.046","article-title":"Protective effect of a dewaxed whole-cell vaccine against Mycobacterium ulcerans infection in mice","volume":"33","author":"M Watanabe","year":"2015","journal-title":"Vaccine"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e0003477","DOI":"10.1371\/journal.pntd.0003477","article-title":"Identification of the Mycobacterium ulcerans Protein MUL_3720 as a Promising Target for the Development of a Diagnostic Test for Buruli Ulcer","volume":"9","author":"A Dreyer","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"ref25","first-page":"150","article-title":"Localization of Mycobacterial Antigens by Immunofluorescence Staining of Agarose Embedded Cells","volume":"4","author":"A Vettiger","year":"2014","journal-title":"J Mycobact Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e16333","DOI":"10.1371\/journal.pone.0016333","article-title":"Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant","volume":"6","author":"RN Coler","year":"2011","journal-title":"PloS One"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1016\/j.vaccine.2013.08.064","article-title":"Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5\/Indonesia\/05\/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant","volume":"31","author":"JJ Treanor","year":"2013","journal-title":"Vaccine"},{"key":"ref28","unstructured":"Portaels F, Johnson P, Meyers WM, Initiative WHOGBU. Buruli ulcer : diagnosis of Mycobacterium ulcerans disease : a manual for health care providers \/ edited by: Fran\u00e7oise Portaels, Paul Johnson, Wayne M. Meyers [Internet]. 2001 [cited 6 Feb 2014]. Available: http:\/\/apps.who.int\/iris\/handle\/10665\/67000<\/ext-link>"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e2252","DOI":"10.1371\/journal.pntd.0002252","article-title":"Geographic distribution, age pattern and sites of lesions in a cohort of Buruli ulcer patients from the Map\u00e9 Basin of Cameroon","volume":"7","author":"MW Bratschi","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e0004011","DOI":"10.1371\/journal.pntd.0004011","article-title":"Use of Recombinant Virus Replicon Particles for Vaccination against Mycobacterium ulcerans Disease","volume":"9","author":"M Bolz","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-1-60327-353-4_13","article-title":"Direct detection of Mycobacterium ulcerans in clinical specimens and environmental samples","volume":"943","author":"CJ Lavender","year":"2013","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1128\/AEM.02971-06","article-title":"Development and application of two multiplex real-time PCR assays for the detection of Mycobacterium ulcerans in clinical and environmental samples","volume":"73","author":"JAM Fyfe","year":"2007","journal-title":"Appl Environ Microbiol"},{"key":"ref33","unstructured":"Portaels F, Organization WH. Laboratory diagnosis of buruli ulcer: a manual for health care providers \/ edited by Fran\u00e7oise Portaels. Diagnostic de l\u2019ulc\u00e8re de Buruli au laboratoire : manuel destin\u00e9 au personnel de sant\u00e9 \/ edit\u00e9 par Fran\u00e7oise Portaels. 2014; Available: http:\/\/apps.who.int\/\/iris\/handle\/10665\/111738<\/ext-link>"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(06)70412-1","article-title":"The role of BCG in prevention of leprosy: a meta-analysis","volume":"6","author":"MS Setia","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1586\/erv.09.161","article-title":"BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control","volume":"9","author":"CSC Merle","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"ref36","first-page":"111","article-title":"BCG vaccination against mycobacterium ulcerans infection (Buruli ulcer). First results of a trial in Uganda","volume":"1","year":"1969","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e3457","DOI":"10.1371\/journal.pntd.0003457","article-title":"Effectiveness of routine BCG vaccination on buruli ulcer disease: a case-control study in the Democratic Republic of Congo, Ghana and Togo","volume":"9","author":"RO Phillips","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3201\/eid1209.050598","article-title":"Risk factors for Buruli ulcer, Benin","volume":"12","author":"M Debacker","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1086\/429623","article-title":"Risk factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-control study in Ghana","volume":"40","author":"PL Raghunathan","year":"2005","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1128\/IAI.69.9.5403-5411.2001","article-title":"Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer","volume":"69","author":"A Tanghe","year":"2001","journal-title":"Infect Immun"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.micinf.2006.03.009","article-title":"Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer","volume":"8","author":"E Coutanceau","year":"2006","journal-title":"Microbes Infect Inst Pasteur"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1371\/journal.pntd.0000199","article-title":"Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting","volume":"2","author":"A Tanghe","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1016\/j.vaccine.2013.09.069","article-title":"TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses","volume":"31","author":"CB Fox","year":"2013","journal-title":"Vaccine"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1016\/j.vaccine.2009.07.081","article-title":"Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion","volume":"27","author":"SL Baldwin","year":"2009","journal-title":"Vaccine"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1128\/IAI.02145-14","article-title":"Protection against Mycobacterium leprae Infection by the ID83\/GLA-SE and ID93\/GLA-SE Vaccines Developed for Tuberculosis","volume":"82","author":"MS Duthie","year":"2014","journal-title":"Infect Immun"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2013.07.030","article-title":"Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis","volume":"172","author":"MT Orr","year":"2013","journal-title":"J Control Release Off J Control Release Soc"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1128\/IAI.69.3.1704-1707.2001","article-title":"Immune response to infection with Mycobacterium ulcerans","volume":"69","author":"TM Gooding","year":"2001","journal-title":"Infect Immun"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1086\/368315","article-title":"Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans","volume":"36","author":"TM Gooding","year":"2003","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3201\/eid0602.000208","article-title":"Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease","volume":"6","author":"KM Dobos","year":"2000","journal-title":"Emerg Infect Dis"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0004431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T09:19:10Z","timestamp":1567588750000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0004431"}},"subtitle":[],"editor":[{"given":"Pamela L. C.","family":"Small","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,2,5]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0004431","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,5]]}}}